AUB ScholarWorks

Antibiotic use and risk of gynecological cancer

Show simple item record

dc.contributor.author Tamim H.M.
dc.contributor.author Musallam K.M.
dc.contributor.author Kadri H.M.A.
dc.contributor.author Boivin J.-F.
dc.contributor.author Collet J.-P.
dc.contributor.editor
dc.date Dec-2011
dc.date.accessioned 2017-10-05T15:37:59Z
dc.date.available 2017-10-05T15:37:59Z
dc.date.issued 2011
dc.identifier 10.1016/j.ejogrb.2011.06.018
dc.identifier.isbn
dc.identifier.issn 03012115
dc.identifier.uri http://hdl.handle.net/10938/16066
dc.description.abstract Objectives: Several studies addressed the association between antibiotic use and breast cancer risk. The objective of this study was to assess the association between antibiotic use and risk of cervical, ovarian, and uterine cancer. Study design: We carried out a population-based case-control study using data from Saskatchewan Health administrative databases (Canada) between the years 1981 and 2000. Cases were matched to 4 controls, using incidence density sampling. The effect of dosage and timing of antibiotic use, over a minimum of 15 years before diagnosis, on cervical, ovarian, or uterine cancer risk was assessed. Number of prescriptions and number of pills were used as exposure definitions. The effect of different classes of antibiotics on cancer risk was also studied. Results: A total of 1225 cancer cases [192 cervical, 445 ovarian, and 588 uterine] and 4900 matched controls were included in this study. Antibiotic exposure (number of prescriptions) during the period of 1-15 years in the past was significantly associated with a reduced risk of cervical cancer; Relative Risk (RR) = 0.40, 0.31, 0.26, and 0.29 for the four exposure quartiles, respectively. No association was found for ovarian or uterine cancer. When number of pills was considered, similar results were found. There was no effect of the timing or class of antibiotic exposure on cervical cancer risk. Conclusions: Antibiotic exposure up to 15 years in the past was associated with a decreased risk of cervical cancer. The lack of temporal trends and the absence of class specific effects suggest a non-causal relationship. Copyright © 2011 Published by Elsevier Ireland Ltd. All rights reserved.
dc.format.extent
dc.format.extent Pages: (388-393)
dc.language English
dc.publisher AMSTERDAM
dc.relation.ispartof Publication Name: European Journal of Obstetrics Gynecology and Reproductive Biology; Publication Year: 2011; Volume: 159; no. 2; Pages: (388-393);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Antibiotic use and risk of gynecological cancer
dc.type Article
dc.contributor.affiliation Tamim, H.M., King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
dc.contributor.affiliation Musallam, K.M., Department of Internal Medicine, Division of Hematology and Oncology, American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Kadri, H.M.A., College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
dc.contributor.affiliation Boivin, J.-F., Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada, Center for Clinical Epidemiology and Community Studies, Lady Davis Institute for Medical Research, Montreal, QC, Canada
dc.contributor.affiliation Collet, J.-P., Department of Pediatrics, University of British Columbia, Child and Family Research Institute, Vancouver, BC, Canada
dc.contributor.authorAddress Tamim, H.M.; King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; email: tamimh@ngha.med.sa
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; Division: Hematology-Oncology;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorDivision Hematology-Oncology
dc.contributor.authorEmail tamimh@ngha.med.sa
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Tamim, HM
dc.contributor.authorInitials Musallam, KM
dc.contributor.authorInitials Al Kadri, HMF
dc.contributor.authorInitials Boivin, JF
dc.contributor.authorInitials Collet, JP
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Tamim, HM (reprint author), King Abdul Aziz Med City Natl Guard, POB 22490, Riyadh 1418, Saudi Arabia.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Anttila T, 2001, JAMA-J AM MED ASSOC, V285, P47, DOI 10.1001-jama.285.1.47; Didham RC, 2005, BREAST CANCER RES TR, V92, P163, DOI 10.1007-s10549-005-2115-8; Downey W, 2000, PHARMACOEPIDEM DR S, P325, DOI 10.1002-0470842555.ch20; Friedman GD, 2006, CANCER EPIDEM BIOMAR, V15, P2102, DOI 10.1158-1055-9965.EPI-06-0401; Kaye JA, 2005, EPIDEMIOLOGY, V16, P688, DOI 10.1097-01.ede.0000172131.84877.42; Kilkkinen A, 2008, INT J CANCER, V123, P2152, DOI 10.1002-ijc.23622; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056-NEJM199210293271804; MANDELL G, 2000, DOUGLAS BENNETTS PRI; MONSON RR, 1976, LANCET, V2, P224; Percy C, 1990, INT CLASSIFICATION D; PLATZCHRISTENSEN JJ, 1994, ACTA OBSTET GYN SCAN, V73, P586, DOI 10.3109-00016349409006278; Rodriguez LAG, 2005, AM J EPIDEMIOL, V161, P616, DOI 10.1093-aje-kwi087; *SAS I INC, 1999, SAS SYST WIND SOFTW; Schlott T, 2005, GYNECOL ONCOL, V98, P409, DOI 10.1016-j.ygyno.2005.04.034; Smith JS, 2002, J NATL CANCER I, V94, P1604; Sorensen HT, 2005, BRIT J CANCER, V92, P594, DOI 10.1038-sj.bjc.6602313; Tamim H, 2006, PHARMACOEPIDEM DR S, V15, P689, DOI 10.1002-pds.1233; Tamim H, 2007, PHARMACOEPIDEM DR S, V16, P250, DOI 10.1002-pds.1360; Tamim HM, 2008, PHARMACOEPIDEM DR S, V17, P144, DOI 10.1002-pds.1512; Velicer CM, 2004, JAMA-J AM MED ASSOC, V291, P827, DOI 10.1001-jama.291.7.827; Viikki M, 2000, ACTA ONCOL, V39, P71; Xu WN, 2006, LANCET ONCOL, V7, P301, DOI 10.1016-S1470-2045(06)70622-2
dc.description.citedCount 2
dc.description.citedTotWOSCount 2
dc.description.citedWOSCount 2
dc.format.extentCount 6
dc.identifier.articleNo
dc.identifier.coden EOGRA
dc.identifier.pubmedID 21741150
dc.identifier.scopusID 82255175110
dc.identifier.url
dc.publisher.address PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Eur. J. Obstet. Gynecol. Reprod. Biol.
dc.relation.ispartOfIssue 2
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle European Journal of Obstetrics Gynecology and Reproductive Biology
dc.relation.ispartofPubTitleAbbr Eur. J. Obstet. Gynecol. Reprod. Biol.
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 159
dc.source.ID WOS:000298526900029
dc.type.publication Journal
dc.subject.otherAuthKeyword Antibiotics
dc.subject.otherAuthKeyword Cervical cancer
dc.subject.otherAuthKeyword Ovarian cancer
dc.subject.otherAuthKeyword Uterine cancer
dc.subject.otherChemCAS cephalosporin, 11111-12-9
dc.subject.otherChemCAS penicillin G, 1406-05-9, 61-33-6
dc.subject.otherChemCAS tetracycline, 23843-90-5, 60-54-8, 64-75-5, 8021-86-1
dc.subject.otherChemCAS Anti-Bacterial Agents
dc.subject.otherChemCAS Anticarcinogenic Agents
dc.subject.otherIndex antibiotic agent
dc.subject.otherIndex cephalosporin
dc.subject.otherIndex macrolide
dc.subject.otherIndex penicillin G
dc.subject.otherIndex sulfonamide
dc.subject.otherIndex tetracycline
dc.subject.otherIndex adult
dc.subject.otherIndex aged
dc.subject.otherIndex antibiotic therapy
dc.subject.otherIndex article
dc.subject.otherIndex Canada
dc.subject.otherIndex cancer risk
dc.subject.otherIndex controlled study
dc.subject.otherIndex data base
dc.subject.otherIndex female
dc.subject.otherIndex gynecologic cancer
dc.subject.otherIndex human
dc.subject.otherIndex incidence
dc.subject.otherIndex major clinical study
dc.subject.otherIndex ovary cancer
dc.subject.otherIndex population based case control study
dc.subject.otherIndex prescription
dc.subject.otherIndex priority journal
dc.subject.otherIndex uterine cervix cancer
dc.subject.otherIndex uterus cancer
dc.subject.otherIndex Adolescent
dc.subject.otherIndex Adult
dc.subject.otherIndex Aged
dc.subject.otherIndex Aged, 80 and over
dc.subject.otherIndex Anti-Bacterial Agents
dc.subject.otherIndex Anticarcinogenic Agents
dc.subject.otherIndex Case-Control Studies
dc.subject.otherIndex Child
dc.subject.otherIndex Child, Preschool
dc.subject.otherIndex Cohort Studies
dc.subject.otherIndex Dose-Response Relationship, Drug
dc.subject.otherIndex Drug Prescriptions
dc.subject.otherIndex Female
dc.subject.otherIndex Humans
dc.subject.otherIndex Incidence
dc.subject.otherIndex Middle Aged
dc.subject.otherIndex Ovarian Neoplasms
dc.subject.otherIndex Risk
dc.subject.otherIndex Saskatchewan
dc.subject.otherIndex State Medicine
dc.subject.otherIndex Uterine Cervical Neoplasms
dc.subject.otherIndex Uterine Neoplasms
dc.subject.otherIndex Young Adult
dc.subject.otherKeywordPlus CERVICAL INTRAEPITHELIAL NEOPLASIA
dc.subject.otherKeywordPlus BREAST-CANCER
dc.subject.otherKeywordPlus CHLAMYDIA-TRACHOMATIS
dc.subject.otherKeywordPlus EXPOSURE
dc.subject.otherKeywordPlus ANTIDEPRESSANTS
dc.subject.otherKeywordPlus CARCINOMA
dc.subject.otherWOS Obstetrics and Gynecology
dc.subject.otherWOS Reproductive Biology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account